Id |
Subject |
Object |
Predicate |
Lexical cue |
T313 |
0-110 |
Sentence |
denotes |
Lili Liu et al. conducted a retrospective analysis of the therapeutic effect of LHQWC in 32 COVID-19 patients. |
T314 |
111-153 |
Sentence |
denotes |
The patients were divided into two groups: |
T315 |
154-303 |
Sentence |
denotes |
Group A + L, in which 18 patients received Abidole (0.2 g, thrice daily) combined with LHQWC; and Group L, in which 14 patients received LHQWC alone. |
T316 |
304-363 |
Sentence |
denotes |
During treatment there was one critical case in each group. |
T317 |
364-469 |
Sentence |
denotes |
Abnormal liver function was observed in 14 cases (77.78%) in Group A + L and 8 cases (57.14%) in Group L. |
T318 |
470-572 |
Sentence |
denotes |
Antibiotic treatment was applied in 17 cases (94.44%) in Group A + L and 13 cases (92.86%) in Group L. |
T319 |
573-673 |
Sentence |
denotes |
Glucocorticoid use was reported in 10 cases (55.56%) in Group A + L and 9 cases (64.29%) in Group L. |
T320 |
674-1048 |
Sentence |
denotes |
Compared with Group L, significantly faster recovery of temperature (t = −2.471, p = 0.019), recovery of respiratory symptoms (t = −2.918, p = 0.007), chest CT inflammation absorption (t = −2.937, p = 0.006), time until two consecutive negative virus nucleic acid tests (t = −2.930, p = 0.006), and shorter hospital stay (t = −2.785, p = 0.009) were observed in Group A + L. |
T321 |
1049-1182 |
Sentence |
denotes |
Abidor combined with LHQWC can be used to treat COVID-19, with good tolerance, to shorten the course of treatment (Liu et al., 2020). |